For example, SNVs were identified in PIK3CA and KRAS across different cancer types and similarly pangenomic markers, such as homologous recombination deficiency (HRD) and tumor mutational burden (TMB), for which clinical trials may be available. This evidence concerns the gene KRAS and neoplasm.